reports
ImprimisRx to Introduce New Formulations at Cataract & Refractive Surg...
ImprimisRx to Introduce New Formulations at Cataract & Refractive Surgery Annual Meeting Eleven relevant presentations are scheduled, covering all five ImprimisRx portfolios SAN DIEGO, April 30, 2019 (GLOBE NEWSWIRE) -- ImprimisRx, the ophthalmology-focused pharmaceutical compounding subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced its participation at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held at the San Diego Convention Center in San Diego, CA May 3-7, 2019. With an estimated 11,000 attendees expected, this is the largest...
Harrow Health Announces Fourth Quarter 2018 Financial Results
Harrow Health Announces Fourth Quarter 2018 Financial Results SAN DIEGO, March 12, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the fourth quarter 2018. Fourth Quarter 2018 and Other Recent Notable Highlights: Revenues increased 55% year-over-year to a new record of $11.4 millionGross Ophthalmology revenue increased 72% year-over-year to a new record of $10 millionGross Margins hit a new record at 64%$18.1 million in Net Income (GAAP)ImprimisRx customers ordering chronic care ophthalmic medicines with refills expected to hit 1,000 by the end of ...
Harrow Health to Attend 31st Annual ROTH Conference on March 18, 2019
Harrow Health to Attend 31st Annual ROTH Conference on March 18, 2019 SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019 at The Ritz Carlton, Laguna Niguel in Dana Point, CA. Mark L. Baum, the company’s Chief Executive Officer, and Andrew R. Boll, its Chief Financial Officer, will be hosting one-on-one meetings at the conference and attendees can contact their Roth Capital Partners representative to arrange a meeting. About Harrow Health Harrow Health, Inc. (NASDAQ:...
Harrow Health to Announce Fourth Quarter 2018 Financial Results on Mar...
Harrow Health to Announce Fourth Quarter 2018 Financial Results on March 12, 2019 SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced it will release fourth quarter 2018 financial results after the close of trading on Tuesday, March 12, 2019. The company will host a conference call at 4:30 p.m. Eastern Daylight Time / 1:30 p.m. Pacific Daylight Time on the same day to discuss the financial results and recent business developments. To participate in the call, please dial (844) 369-8770 for domestic callers or (862) 298-0840 for international ca...
Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid ...
Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain and Sedation Formulations Issuance of new patents strengthens the intellectual property around Melt Pharmaceuticals’ flagship drug candidate and potential label extensions SAN DIEGO and BOSTON, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Melt Pharmaceuticals, Inc., a specialty pharmaceutical company recently deconsolidated from Harrow Health, Inc. (NASDAQ: HROW), today announced the U.S. Patent and Trademark office has issued two additional patents covering the company’s innovative sublingual, non-opioid pain and sedation ...
Harrow Health Subsidiary, Mayfield Pharmaceuticals, Inc., Acquires Pat...
Harrow Health Subsidiary, Mayfield Pharmaceuticals, Inc., Acquires Patented Dyspareunia Drug Candidate and Other Intellectual Property Mayfield, a women’s health focused drug development company, intends to seek FDA approval for MAY-44 Dyspareunia treatment drug candidate via the 505(b)(2) approval pathway SAN DIEGO, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), today announced that its subsidiary, Mayfield Pharmaceuticals, Inc., has acquired drug formulation assets and intellectual property, including three recently issued patents, from Elle Pharmaceutical, LLC,...
Harrow Health Announces $11 Million Series A Financing for Melt Pharma...
Harrow Health Announces $11 Million Series A Financing for Melt Pharmaceuticals Subsidiary Investment will enable Melt to fund the development of its patented, non-opioid sublingual sedation and analgesia drug candidate, MELT-100 SAN DIEGO and BOSTON, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Melt Pharmaceuticals, Inc., an affiliated company of Harrow Health, Inc. (NASDAQ: HROW), today announced it has entered into definitive stock purchase agreements with accredited and institutional investors to raise proceeds of approximately $11 million in a private placement sale of its Series A preferred ...
Imprimis Pharmaceuticals, Inc. Completes Name Change to Harrow Health,...
Imprimis Pharmaceuticals, Inc. Completes Name Change to Harrow Health, Inc. Harrow Health, Inc. Name Reflects the Company’s Commitment to the Future of Healthcare SAN DIEGO, Dec. 31, 2018 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (formerly known as Imprimis Pharmaceuticals, Inc.) (NASDAQ: IMMY) announced it has formally changed its name and that it will trade as “HROW” on The NASDAQ Capital Markets beginning at market open January 2, 2019. Mark L. Baum, CEO of Harrow Health, stated, “Our new name reflects our business model of creating, investing in, operating and growing a diversified ...
Imprimis Pharmaceuticals Ranked 88th Fastest Growing Company in North ...
Imprimis Pharmaceuticals Ranked 88th Fastest Growing Company in North America on Deloitte’s 2018 Technology Fast 500™ Imprimis attributes growth to its vision of making sure patients have access to high quality affordable medications SAN DIEGO, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today announced that it ranked 88th on ™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. Winners were selected based on percentage fiscal year revenue growth from 2014 to 2017,...
Imprimis Pharmaceuticals Announces Third Quarter 2018 Results
Imprimis Pharmaceuticals Announces Third Quarter 2018 Results SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported results for the third quarter 2018. Third Quarter 2018 and Other Recent Notable Highlights: Revenues increased 66% year-over-year to $10.7 millionOphthalmology revenue increased 81% year-over-year to $8.9 millionGross margin increased to 61% from 48% in the third quarter 2017Second consecutive quarter of positive adjusted EBITDA (a non-GAAP measure) of $424,000Cash balance increased for the second consecutive quarterTermi...
Imprimis Pharmaceuticals to Announce Third Quarter 2018 Financial Resu...
Imprimis Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 13, 2018 SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today announced it will release third quarter 2018 financial results after the close of trading on Tuesday, November 13, 2018. The company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day to discuss the financial results and recent business developments. To participate in the call, please dial (877) 407-8031 for domestic callers or (201) 689-8031 for internat...
Imprimis Pharmaceuticals’ Subsidiary Melt Pharmaceuticals Initiates ...
Imprimis Pharmaceuticals’ Subsidiary Melt Pharmaceuticals Initiates Clinical Development Program for its Patented Non-Opioid and Non-Invasive MK Melt™ Conscious Sedation Drug Candidate FDA Grants Pre-IND Meeting; Two Investigator-led Studies on Melt Formulations to Commence in Q4 SAN DIEGO, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Melt Pharmaceuticals, a subsidiary of Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), today announced that following the presentation of clinical data on the MKO Melt® (midazolam/ketamine/ondansetron) from a 611-patient IRB approved prospective, controlled, randomized...
ImprimisRx to feature new formulation and poster presentation on MKO M...
ImprimisRx to feature new formulation and poster presentation on MKO Melt® at the upcoming American Academy of Ophthalmology Meeting in Chicago Poster on data from a 611-patient study featuring Imprimis’s MKO Melt to be presented SAN DIEGO, Oct. 16, 2018 (GLOBE NEWSWIRE) -- ImprimisRx, the ophthalmic-focused division of Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), today announced its participation at the upcoming 2018 American Academy of Ophthalmology (AAO) Annual Meeting to be held at the McCormick Place Convention Center in Chicago, IL, October 26-30. The American Academy of Ophthal...
Imprimis Pharmaceuticals to Announce Second Quarter 2018 Financial Res...
Imprimis Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 6, 2018 SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today announced it will release second quarter 2018 financial results after the close of trading on Monday, August 6, 2018. The company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day to discuss the financial results and recent business developments. To participate in the call, please dial (877) 407-8031 for domestic callers or (201) 689-8031 for international...
Ford Equity US Rating and Forecast Report
Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
QuickView: Building revenue streams
Imprimis is poised to achieve meaningful revenue in 2015. In 2014 it increased capacity by acquiring two compounding pharmacies and thus increased sales of its ophthalmic products. 2015 has seen continued adoption of the Dropless Therapy cataract surgery injection and the acquisition of the exclusive licence to Hep-Lido-A (HLA), which sold 80k units last year. Revenue is likely to rise in 2015, with strong upside potential if targeted increases in market share are achieved.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.